Derinat (sodium desoxyribonucleate)
/ PharmPak
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
March 04, 2023
Derinat extends hair cycle at anagen phase by decreasing the level of TRPCs-mediated intracellular ROS accumulation in skin
(ISID 2023)
- "Our study demonstrated that Derinat with hair restorer efficacy in mice was due to maintenance of the hair cycle at the anagen phase, relating to the decreased level of TRPCs-mediated intracellular ROS accumulation."
Inflammation
January 17, 2023
Derinat has an immunomodulatory and anti-inflammatory effect on the model of acute lung injury in male SD rats.
(PubMed, Front Pharmacol)
- "Thus, the administration of Derinat stimulates the immune response, has a pronounced protective effect against cytokinemia and respiratory failure caused by ALI, has immunomodulatory effect, and also stimulates a local immune response in lung tissues. Thus, Derinat is a promising treatment for ALI."
Immunomodulating • Journal • Preclinical • Acute Lung Injury • Hematological Disorders • Immune Modulation • Inflammation • Respiratory Diseases
December 03, 2021
Experimental Study of the Efficacy of Sodium Deoxyribonucleate Used in Combination with Co-Transplantation of Mesenchymal and Hematopoietic Stem Cells after Exposure to γ-Radiation.
(PubMed, Bull Exp Biol Med)
- "Single or double administration of Derinat prior to irradiation was ineffective. The optimal result was obtained when the following scheme was applied: MSC→HSC with an interval of 48 h starting during the first hours after irradiation and triple administration of Derinat (in 10-15 min, 3 and 7 days after irradiation) in a dose of 3 mg/mouse."
Clinical • Combination therapy • Journal • Aplastic Anemia • Hematological Disorders • Immune Modulation • Inflammation • Transplantation
1 to 3
Of
3
Go to page
1